Month: April 2021

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.215309-01-6,3-(4-Methylpiperazin-1-yl)benzoic acid,as a common compound, the synthetic route is as follows.

General procedure: A solution of 2-(2-methyl-1H-indol-1-yl)ethanamine (4a) (65 mg, 0.373 mmol) and 4-(piperidin-1-yl)benzoic acid (5) (76 mg, 1 eq.), and dimethylaminopyridine (catalytic, ?5 mg) in dichloromethane (6 mL) was added 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide.hydrochloride (EDCI) (92 mg, 1.3 eq.) at room temperature. The resulting reaction mixture was stirred for 6h. At the conclusion of the reaction (TLC), water (15 mL) was added to quench the reaction. The product was extracted with ethyl acetate (20mL¡Á3). Organics were washed with dilute HCl (10 mL), saturated NaHCO3 solution (10 mL), water (10 mL) and brine solution (10 mL) and dried over Na2SO4 and concentrated. The resulting crude product was subjected to silica gel chromatography eluting with 0-40% ethyl acetate in hexane to furnish 7k (TG7-152) (100mg, 74% yield). 1H NMR (CDCl3): delta 7.52 (d, J=5.6Hz, 1H), 7.49 (d, J=8.8Hz, 2H), 7.30 (d, J=8Hz, 1H), 7.07 (m, 2H), 6.80 (d, J=8.2Hz, 2H), 6.23 (s, 1H), 5.98 (t, J=5.4Hz, 1H), 4.33 (t, J=6Hz, 2H), 3.76 (q, J=6Hz, 2H), 3.25 (t, J=4.8Hz, 4H), 2.37 (s, 3H), 1.6 (m, 6H). LCMS (ESI): >97% purity at lambda 254, MS; m/z, 362 [M+H]+. Anal. Calcd. for C23H27N3O: C, 76.42; H, 7.53; N, 11.62; found; C, 76.48; H, 7.55; N, 11.59.

215309-01-6, As the paragraph descriping shows that 215309-01-6 is playing an increasingly important role.

Reference£º
Article; Ganesh, Thota; Jiang, Jianxiong; Dingledine, Ray; European Journal of Medicinal Chemistry; vol. 82; (2014); p. 521 – 535;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.13484-40-7,1-(2-Methoxyethyl)piperazine,as a common compound, the synthetic route is as follows.

To a solution containing 2.7 g (18.9 mmol) of 1-[2-(methyloxy)ethyl]piperazine and 20 ml. of THF at O0C was added 0.9 g (23 mmol) of a 60% suspension of NaH in mineral oil. The reaction mixture was allowed to stir for 15 min and 3.0 g (18.9 mmol) of 2- chloro-5-nitropyridine was added. The reaction mixture was heated at 6O0C overnight and then quenched by the addition of water and extracted with EtOAc. The combined organic layers were dried over MgSO4 and the solvents were removed under reduced pressure. The residue was subjected to silica gel chromatography to give 2.7 g (54%) of 1-[2-(methyloxy)ethyl]-4-(5-nitro-2-pyridinyl)piperazine as a yellow solid: 1H NMR (400 MHz, DMSO-d6) delta 2.50-2.53 (m, 6H), 3.24 (s, 3 H), 3.46 (t, J = 5.7 Hz, 2 H), 3.71 – 3.78 (m, 4 H), 6.94 (d, J = 9.7 Hz, 2 H), 8.21 (dd, J = 9.6 and 2.8 Hz, 1 H), and 8.95 (d, J = 2.75 Hz, 1 H)., 13484-40-7

As the paragraph descriping shows that 13484-40-7 is playing an increasingly important role.

Reference£º
Patent; SMITHKLINE BEECHAM CORPORATION; WO2009/32667; (2009); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.934-98-5,2-(4-Methylpiperazin-1-yl)ethanamine,as a common compound, the synthetic route is as follows.,934-98-5

Will 97 (0.30g, 0.88mmol),EDC.HCl (0.25 g, 1.32 mmol),HOBt (0.14 g, 1.06 mmol),A mixture of NMM (0.23 ml, 2.11 mmol) and DMF (2.5 ml) was stirred for a while, then 2-(4-methylhexahydropyrazin-1-yl)ethanamine (0.16 ml, 1.06) was added thereto at room temperature. Mmol) and stir overnight.The residue was purified by flash column on silica gel (dichloromethane:methanol=9:1, Rf=0.19) to give 49 (0.08 g, 19.47percent) as a red solid.

The synthetic route of 934-98-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; TAIPEI MEDICAL UNIVERSITY (TW); YEN, YUN (US); LIOU, JING PING (TW); PAN, SHIOW LIN (TW); (56 pag.)TW2018/5267; (2018); A;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.75336-86-6,(R)-2-Methylpiperazine,as a common compound, the synthetic route is as follows.

75336-86-6, EXAMPLE 26A (3R)-3-methyl-1-pyridin-2-ylpiperazine (R)-(-)-2-Methylpiperazine (0.50 g, 0.005 mol, Aldrich) and 2-bromopyridine (5 mL, 0.05 mol) were combined and heated at 120¡ã C. for 14 hours. The reaction mixture was allowed to cool to 23¡ã C. and partitioned between a large volume of ethyl acetate and water. The layers were separated, and then additional water was added to the ethyl acetate solution. Drops of 1 N HCl solution were added to the water/ethyl acetate mixture with vigorous mixing. The layers were separated, and the combined aqueous phases were basified to pH~11 with a solution of saturated sodium bicarbonate and solid sodium carbonate. Sodium chloride was added, and the saturated aqueous solution was extracted with chloroform containing a few drops of isopropyl alcohol (5*). The combined organic extracts were dried over Na2SO4, filtered, and the filtrate concentrated under reduced pressure to afford 0.79 g (89percent yield) of the title compound. 1H NMR (400 MHz, DMSO-d6) delta 1.02 (d, J=6.0 Hz, 3H), 2.27 (dd, J=10, 12 Hz, 1), 2.67 (m, 3H), 2.92 (m, 1H), 4.07 (m, 2H), 6.58 (dd, J=6, 8 Hz, 1H), 6.77 (d, J=8 Hz, 1H), 7.49 (m, 1H), 8.08 (m, 1H); MS (ESI) m/e 178 (M+H)+.

As the paragraph descriping shows that 75336-86-6 is playing an increasingly important role.

Reference£º
Patent; Cowart, Marlon D.; Patel, Meena V.; Kolasa, Teodozyi; Brioni, Jorge D.; Rohde, Jeffrey J.; Engstrom, Kenneth M.; Stewart, Andrew O.; Daanen, Jerome F.; Bhatia, Pramila A.; US2004/127504; (2004); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1030377-21-9,(S)-1-Boc-2-(Hydroxymethyl)piperazine,as a common compound, the synthetic route is as follows.

To a solution of (S)-l-Boc-2-hydroxymethylpiperazine (1.0 g, 4.62 mmol) in DCE (92.47 ml, 4.624 mmol) was added formaldehyde (3.474 ml, 46.24 mmol) (37% in water) followed by sodium triacetoxyborohydnde (4.9 g, 23.12 mmol). The mixture was stirred vigorously at room temperature for 2.5hours. The mixture was treated with saturated sodium bicarbonate (30 mL), stirred for 10 min then extracted with DCM (3 x 10 mL). The combined organic phases were dried over sodium sulfate, filtered and concentrated. ES+APCI MS m/z 231.1 [M+H]+., 1030377-21-9

The synthetic route of 1030377-21-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; MIRATI THERAPEUTICS, INC.; ARRAY BIOPHARMA, INC.; FISCHER, John, P.; FELL, Jay, Bradford; BLAKE, James, F.; HINKLIN, Ronald, Jay; MEJIA, Macedonio, J.; HICKEN, Erik, James; CHICARELLI, Mark, Joseph; GAUDINO, John, J.; VIGERS, Guy, P.A.; BURGESS, Laurence, E.; MARX, Matthew, Arnold; CHRISTENSEN, James, Gail; LEE, Matthew, Randolf; SAVECHENKOV, Pavel; ZECCA, Henry, J.; (529 pag.)WO2017/201161; (2017); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.20327-23-5,1-Cyclopropylpiperazine,as a common compound, the synthetic route is as follows.

20327-23-5, Example 34N-(2-aminophenyl)-4-(4-(4-(6-(4-cyclopropylpiperazin-1-yl)pyridin-3-yl)thiazol-2-yl)tetrahydropyran-4-yl)benzamide; 4-(4-thiocarbamoyl-tetrahydro-pyran-4-yl)-benzoic acid methyl ester (700 mg, 2.50 mmol), in MeOH was combined with 2-Bromo-1-(6-chloro-pyridin-3-yl)-ethanone (800 mg, 1.1 eq) and heated at 65 C. for 2 hours. After reaction was complete, the reaction mixture was evaporated, diluted with EtOAc, and washed with a saturated aqueous NaHCO3 and brine. The organic phase was dried over MgSO4 and evaporated.4-{4-[4-(6-chloro-pyridin-3-yl)-thiazol-2-yl]-tetrahydro-pyran-4-yl}-benzoic acid methyl ester was dissolved in MeOH and 1N NaOH was added. After the reaction was done, the reaction mixture was evaporated, suspended in water, and neutralized with 1N HCl. The formed solids were collected by filtration. The solids were then suspended in acetonitrile and filtered to have a clean product 4-{4-[4-(6-chloro-pyridin-3-yl)-thiazol-2-yl]-tetrahydro-pyran-4-yl}-benzoic acid. Compound 4-{4-[4-(6-chloro-pyridin-3-yl)-thiazol-2-yl]-tetrahydro-pyran-4-yl}-benzoic acid (150 mg, 0.375 mmol) was dissolved in DMF. Then, 1-cyclopropyl-piperazine (82 mg, 1.1 eq), and DIPEA (0.2 mL, 3.2 eq) were added, and the reaction mixture was heated in the microwave at 90 C. for 30 minutes. After reaction was done, the reaction mixture was extracted with EtOAc. The organic phase was dried with MgSO4 and evaporated to have the solid material 4-(4-{4-[6-(4-cyclopropyl-piperazin-1-yl)-pyridin-3-yl]-thiazol-2-yl}-tetrahydro-pyran-4-yl)-benzoic acid.4-(4-{4-[6-(4-cyclopropyl-piperazin-1-yl)-pyridin-3-yl]-thiazol-2-yl}-tetrahydro-pyran-4-yl)-benzoic acid (60 mg, 0.122 mmol), benzene-1,2-diamine (26 mg, 2.0 eq), HATU (56 mg, 1.2 eq), and DIPEA (0.042 mL, 2.1 eq) were dissolved in DMF and stirred at room temperature for 2 hours. After the reaction was complete, the reaction mixture was extracted with EtOAc and water. The organic phase was dried with MgSO4 and evaporated. The solid was purified by reverse phase chromatography to afford title compound. MS found for C33H36N6O2S as (M+H)+ 581.56. 1H NMR (400 MHz, dmso-d6): delta: 9.24 (s, 1H), 8.35 (s, 1H), 7.68 (d, J=6.2 Hz, 1H), 7.60 (d, J=8.2 Hz, 2H), 7.51 (s, 1H), 7.23 (d, J=8.4 Hz, 2H), 6.79 (d, J=7.2 Hz, 1H), 6.62-6.51 (m, 2H), 6.41 (d, J=7.4 Hz, 1H), 6.22 (t, J=5.2 Hz, 1H), 4.51 (s, 2H), 3.45-3.38 (m, 2H), 3.32-3.25 (m, 2H), 3.18-3.11 (m, 4H), 2.38-2.22 (m, 6H), 2.15-2.05 (m, 2H), 1.31-1.23 (m, 1H), 0.12-0.1 (m, 4H).

The synthetic route of 20327-23-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Melvin, JR., Lawrence S.; Graupe, Michael; Venkataramani, Chandrasekar; US2010/22543; (2010); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.314741-40-7,(S)-tert-Butyl 3-(hydroxymethyl)piperazine-1-carboxylate,as a common compound, the synthetic route is as follows.

Step D: tert-butyl (3S)-4-[2-(3-cyano-4-fluorophenyl)-2-oxoethyl] -3-(hydroxymethyl)piperazine-1-carboxylate: 5-(Bromoacetyl)-2-fluorobenzonitrile (590 mg, 2.44 mmol) and (S)-4-N-BOC-2-hydroxymethyl-piperazine (527 mg, 2.44 mmol) were dissolved in THF (40 mL) at 0C thenTEA (247 mg, 2.44 mmol) was added. The reaction mixture was stirred at RT for 16 h, thenpoured into water and extracted with ethyl acetate. The organic layer was dried over Na2SO4,filtered, and evaporated to dryness. The crude product was purified by MPLC through an 80gRedi-sep column using 0-100% EtOAc/hexane to yield the title compound., 314741-40-7

The synthetic route of 314741-40-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; MERCK SHARP & DOHME CORP.; PASTERNAK, Alexander; DEJESUS, Reynalda, Keh; FRIE, Jessica, L.; PIO, Barbara; TANG, Haifeng; WALSH, Shawn, P.; WO2014/99633; (2014); A2;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.129779-30-2,(3R,5S)-rel-tert-Butyl 3,5-dimethylpiperazine-1-carboxylate,as a common compound, the synthetic route is as follows.

To a solution of compound 1 (1 eq) in ethanol (10 mL), TEA (3 eq) and 2,2-dimethyloxirane (1.5 eq) were added and the reaction mixture was heated at 80 C for 12 h. The progress of reaction was monitored by TLC. After completion, the reaction mixture was allowed to cool, concentrated to give a crude compound which was purified by silica gel column chromatography to afford the desired compound 2b., 129779-30-2

As the paragraph descriping shows that 129779-30-2 is playing an increasingly important role.

Reference£º
Patent; BIOMARIN PHARMACEUTICALS INC.; LUEDTKE, Gregory; BHAGWAT, Shripad; (99 pag.)WO2018/119362; (2018); A2;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.34334-28-6,4-(4-Methylpiperazin-1-yl)benzonitrile,as a common compound, the synthetic route is as follows.

4-(4-Methylpiperazin-1-yl)benzonitrile (0.035 mmol, 7 g) was dissolved inconcentrated HC1 (10 ml) at 0C and the resulting solution was immediately warmed up to100C and stirred for 5h. The solvent was removed and the residue was dried affording the title compound as a white solid (6.5 g, 73%).(ESI+) MS: m/z 221.2 (MHj.

34334-28-6, The synthetic route of 34334-28-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; EUDENDRON S.R.L.; UNIVERSITA’ DEGLI STUDI DI MILANO; ANGIOLINI, Mauro; ZUCCOTTO, Fabio; BERNARDI, Anna; AIRAGHI, Francesco; (144 pag.)WO2016/96709; (2016); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.108-49-6,2,6-Dimethylpiperazine,as a common compound, the synthetic route is as follows.

2-(lH-Indazol-4-ylV6-rf3R.5S)-4-(2-methoxy-ethylV3,5-dimethyl-piperazin-l- ylmethyl]-4-mophiholin-4-yl-thienof3,2-d]pyrimidine (98).Prepared via 2-Chloro-6-[(3R,5S)-4-(2-methoxy-ethyl)-3,5-dimethyl- piperazin- 1 -ylmethyl]-4-mophiholin-4-yl-thieno[3,2-d]pyrimidine, prepared from (2R,6S)- 1 -(2-methoxy-ethyl)-2,6-dimethyl-piperazine.Amine preparation: to a solution of 2,6-dimethylpiperazine (predominantly cis) (250mg), te?t-butanol (2.5mL), sodium hydroxide (88mg) and water (0.5mL) was added a solution of di-tert-butyl-dicarbonate (478mg) in tert-butanol (0.5mL). After stirring overnight, the reaction mixture was diluted with ethyl acetate, washed with brine, dried (MgSO4) and the solvent was removed in vacuo to yield (3R,5S)- 3,5-dimethyl-piperazine-l-carboxylic acid tert-butyl ester (400mg).A mixture of (3R,5S)-3,5-dimethyl-piperazine-l-carboxylic acid tert-butyl ester (1.5g), 2-bromoethyl methyl ether (1.32mL) and potassium carbonate (1.06g) was heated to 1200C in DMF (15mL) for 2 days. The reaction mixture was cooled, diluted with ethyl acetate, washed with brine, dried (MgSO4) and the solvent was removed in vacuo to liberate (3R,5S)-4-(2-methoxy-ethyl)-3,5-dimethyl-piperazine- 1-carboxylic acid tert-butyl ester (1.4g) after column chromatography.Removal of the BOC group with HCl yielded the desired compound, which was isolated as the hydrochloride salt. EPO -Sl-1H NMR (400MHz, CDCl3): 1.01 (6H, d), 1.9 (2H, m), 2.61 (4H, m), 2.82 (2H, t), 3.27 (3H, s), 3.37 (2H, t), 3.71 (2H, s), 3.85 (4H,m), 4.02 (4H,m), 7.3 (IH, s), 7.43 (IH, t), 7.51 (IH, d), 8.21 (IH, d), 8.95 (lH,s), 10.10 (IH, m); MS (ESf) 522.35 (MH+).

108-49-6, 108-49-6 2,6-Dimethylpiperazine 66056, apiperazines compound, is more and more widely used in various fields.

Reference£º
Patent; PIRAMED LIMITED; WO2006/46031; (2006); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics